Indiana University School of Medicine scientists have identified a promising drug target for Alzheimer’s disease. The team found that removing an enzyme from neurons in the brain substantially reduces amyloid plaques—a hallmark characteristic of the disease—and may provide further resilience against disease progression.
Read more HERE
In a world’s first, an NIH-funded randomized controlled trial of more than 2,800 older adults (the “ACTIVE Study”) has reported a modest amount of cognitive training significantly reduced Alzheimer Disease and related dementias diagnoses, as reported in Medicare data over a 20-year follow-up period. The results are published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions,
Read the article about it HERE
Patients with dementia who participated in a Medicare-funded collaborative care program that provided support and medical advice for caregivers were able to remain in their home communities longer before entering nursing homes, according to a new study. This compares to those patients who were taking lecanemab, one of two approved drugs that have been shown to slow progression of Alzheimer’s in some patients, a February study published in Alzheimer’s & Dementia: Behavior & Socioeconomics of Aging found.
Scientists have found a potential new way to slow memory loss in Alzheimer’s, a neurodegenerative disorder that gradually damages memory and thinking, according to a new study.
Read it all HERE
Scientists at Tokyo Metropolitan University have turned to polymer physics to better understand one of the defining features of Alzheimer’s disease: the formation of tau protein fibrils. Their research shows that these fibrils do not form directly. Instead, tau proteins first gather into large clusters, similar to how polymers begin to crystallize. When researchers disrupted these early clusters, fibrils failed to develop in solution.
This finding points to a major shift in how future treatments for neurodegenerative diseases might be designed.
Read the article HERE
Researchers have created a targeted compound that blocks an enzyme linked to inflammation in individuals with a genetic predisposition to Alzheimer’s disease, while still maintaining normal brain activity and successfully passing through the blood-brain barrier.
Scientists at the University of Southern California report that they have found new druglike compounds that could calm a major source of brain inflammation tied to Alzheimer’s disease. The study was just published in the Nature journal npj Drug Discovery.
Read all about it HERE